314 related articles for article (PubMed ID: 17123392)
1. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():37-41; discussion 41-2. PubMed ID: 17123392
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors in congenital coagulation disorders.
Key NS
Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors in young boys with haemophilia.
Lusher JM
Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
[TBL] [Abstract][Full Text] [Related]
4. Recent improvements in the clinical treatment of coagulation factor inhibitors.
Franchini M; Lippi G
Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
6. Urgent inhibitor issues: targets for expanded research.
Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():107-13. PubMed ID: 17123403
[TBL] [Abstract][Full Text] [Related]
7. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
8. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
Gouw SC; van den Berg HM
Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
[TBL] [Abstract][Full Text] [Related]
9. How to manage invasive procedures in children with haemophilia.
Ljung RC; Knobe K
Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
[TBL] [Abstract][Full Text] [Related]
10. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
Chitlur M; Warrier I; Rajpurkar M; Lusher JM
Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
[TBL] [Abstract][Full Text] [Related]
12. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
[TBL] [Abstract][Full Text] [Related]
13. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
Rup B
Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
[TBL] [Abstract][Full Text] [Related]
15. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
[TBL] [Abstract][Full Text] [Related]
16. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
Astermark J
Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
[TBL] [Abstract][Full Text] [Related]
17. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
Astermark J
Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
[TBL] [Abstract][Full Text] [Related]
18. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
20. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
